Browsing by Author "Ateş, Kenan"
Now showing 1 - 3 of 3
- Results Per Page
- Sort Options
Article Citation Count: 0COVID-19 Infection in Peritoneal Dialysis Patients: \rA Comparative Outcome Study with Patients on \rHemodialysis and Patients without Kidney Disease(Aves, 2022) Kazancıoğlu, Rümeyza; Ozturk, Savas; Turgutalp, Kenan; Gürsu, Meltem; Arıcı, Mustafa; Oruç, Ayşegül; Ateş, KenanObjectives: There is limited data about coronavirus disease-19 (COVID-19) characteristics and results in peritoneal dialysis \r(PD) patients. This study aimed to investigate the characteristics and outcomes among PD patients and compare them with \rmatched hemodialysis (HD) patients and a control group without kidney disease.\rMethods: We included 18 PD patients and consecutive age- and gender-matched 18 HD and 18 patients without kidney \rdisease (control group) registered into the Turkish Society of Nephrology database including 1301 COVID-19 patients. We \rcompared demographic, clinical, radiological, laboratory data, and outcomes namely intensive care unit (ICU) admission, \rmechanical ventilation, mortality, and composite outcome (death and/or ICU admission).\rResults: ICU admission, mechanical ventilation, and mortality rates in PD patients (27.8%, 22.2%, and 22.2%, respectively) \rand the HD group (16.7%, 11.1%, and 16.7%, respectively) were higher than the control group (11.1%, 11.1%, and 5.6%, \rrespectively), but intergroup comparison did not reveal difference. A total of 11 (20.3%) patients had composite outcome \r(6 PD patients, 3 HD patients, and 2 patients in the control group). In Cox regression analysis, higher age and higher CRP level were related to increased risk of composite outcome. Adjusted rate of composite outcome in PD group was significantly higher than \rthe control group (P = .050). This rate was similar in HD and control groups (P = .30).\rConclusions: Combined in-hospital mortality and/or ICU admission of PD patients with COVID-19 was significantly higher than the control \rpatients. There is a need for careful surveillance of PD patients for infection signs and prompt treatment of COVID-19.Article Citation Count: 1Impact of hospital-acquired acute kidney injury on Covid-19 outcomes in patients with and without chronic kidney disease: a multicenter retrospective cohort study(Tubitak Scientific & Technological Research Council Turkey, 2021) Ozturk, Savas; Turgutalp, Kenan; Arıcı, Mustafa; Çetinkaya, Hakkı; Altıparmak, Mehmet Rıza; Aydın, Zeki; Ateş, KenanBackground/aim: Hospital-acquired acute kidney injury (HA-AKI) may commonly develop in Covid-19 patients and is expected to have higher mortality. There is little comparative data investigating the effect of HA-AKI on mortality of chronic kidney disease (CKD) patients and a control group of general population suffering from Covid-19. Materials and methods: HA-AKI development was assessed in a group of stage 3–5 CKD patients and control group without CKD among adult patients hospitalized for Covid-19. The role of AKI development on the outcome (in-hospital mortality and admission to the intensive care unit [ICU]) of patients with and without CKD was compared. Results: Among 621 hospitalized patients (age 60 [IQR: 47–73]), women: 44.1%), AKI developed in 32.5% of the patients, as stage 1 in 84.2%, stage 2 in 8.4%, and stage 3 in 7.4%. AKI developed in 48.0 % of CKD patients, whereas it developed in 17.6% of patients without CKD. CKD patients with HA-AKI had the highest mortality rate of 41.1% compared to 14.3% of patients with HA-AKI but no CKD (p < 0.001). However, patients with AKI+non-CKD had similar rates of ICU admission, mechanical ventilation, and death rate to patients with CKD without AKI. Adjusted mortality risks of the AKI+non-CKD group (HR: 9.0, 95% CI: 1.9–44.2) and AKI+CKD group (HR: 7.9, 95% CI: 1.9–33.3) were significantly higher than that of the non-AKI+non-CKD group. Conclusion: AKI frequently develops in hospitalized patients due to Covid-19 and is associated with high mortality. HA-AKI has worse outcomes whether it develops in patients with or without CKD, but the worst outcome was seen in AKI+CKD patients.Key words: Acute kidney injury, chronic kidney disease, Covid-19, hospitalization, mortalityArticle Citation Count: 0Main Outcomes of the DIYAL-TR Study: Regional\rDifferences of Mortality and Morbidity in Chronic\rHemodialysis Patients(Aves, 2022) Sezer, Siren; Kızılırmak, Pınar; Ecder, Süleyman Tevfik; Ateş, Kenan; Arıcı, Mustafa; Sezer, Siren; Kaptanoğulları, Hakan; Arınsoy, Selim TurgayObjective: Variations in care at national or global level may have an impact on the prognosis of patients on chronic hemodialysis.\rWe aimed to describe regional differences in all-cause mortality or cardiovascular morbidity in chronic hemodialysis\rpatients in Turkey.\rMethods: We enrolled 2461 patients who were initiated chronic hemodialysis in 93 centers in Turkey between January 27,\r2017, and February 09, 2018. We included 2-year follow-up data of 1877 patients in this prospective study. The primary\routcome, the rate of composite endpoint of all-cause mortality or cardiovascular morbidity, was compared between geographical\rregions. Secondary outcomes were the rates of hospitalization and infections.\rResults: In total, 552 patients (29.4%) developed the primary outcome. The highest and lowest rates of primary outcome\roccurred in the Mediterranean (34.5%) and Southeastern (26.5%) & Central Anatolian regions (26.5%), respectively, with no\rsignificant differences across regions (P = .82). Hospitalization events were detected in 377 patients (20.1%). The highest\rrate of hospitalization was detected in the Black Sea region (33.8%), and the lowest (7.6%) in the Southeastern region. The\rregions did not differ in hospitalization rates (P = .88). Infections occurred in 11.3% (n = 212) of the patients. The highest and\rlowest rates of infections occurred in the Aegean (18.2%) and the Southeastern (2.9%) regions, respectively. We detected\rsignificant difference between geographic regions (P = .02).\rConclusions: Our study showed that almost 3 in every 10 chronic hemodialysis patients reached the primary endpoint\rof all-cause mortality/cardiovascular morbidity during the 2 years of follow-up. The occurrence of this outcome does not\rseem to exhibit geographical variation across the country.